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SHORT COMMUNICATION
T-bet is essential for Th1-mediated, but not
Th17-mediated, CNS autoimmune disease
Richard A. O’Connor, Helen Cambrook, Katja Huettner
and Stephen M. Anderton
Medical Research Council Centre for Inflammation Research, Centre for Multiple Sclerosis
Research and Centre for Immunity Infection and Evolution, Queen’s Medical Research
Institute, University of Edinburgh, Edinburgh, UK
T cells that produce both IL-17 and IFN-γ, and co-express ROR-γt and T-bet, are often
found at sites of autoimmune inflammation. However, it is unknown whether this co-
expression of T-bet with ROR-γt is a prerequisite for immunopathology. We show here
that T-bet is not required for the development of Th17-driven experimental autoimmune
encephalomyelitis (EAE). The disease was not impaired in T-bet−/− mice and was asso-
ciated with low IFN-γ production and elevated IL-17 production among central nervous
system (CNS) infiltrating CD4+ T cells. T-bet−/− Th17 cells generated in the presence of
IL-6/TGF-β/IL-1 and IL-23 produced GM-CSF and high levels of IL-17 and induced disease
upon transfer to naı¨ve mice. Unlike their WT counterparts, these T-bet−/– Th17 cells did
not exhibit an IL-17→IFN-γ switch upon reencounter with antigen in the CNS, indicating
that this functional change is not critical to disease development. In contrast, T-bet was
absolutely required for the pathogenicity of myelin-responsive Th1 cells. T-bet-deficient
Th1 cells failed to accumulate in the CNS upon transfer, despite being able to produce
GM-CSF. Therefore, T-bet is essential for establishing Th1-mediated inflammation but is
not required to drive IL-23-induced GM-CSF production, or Th17-mediated autoimmune
inflammation.
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See accompanying article by Grifka-Walk et al. and commentary by Spath and Becher
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
An illuminating series of studies over the past 5 years has led to the
appreciation that, far from being members of categorically fixed
subsets, CD4+ T cells can switch their expression of transcrip-
tion factors and therefore downstream effector functions includ-
ing cytokines, dependent on the inflammatory environment they
Correspondence: Prof. Stephen M. Anderton
e-mail: steve.anderton@ed.ac.uk
find themselves in [1]. An excellent pathological example of this
T-cell plasticity comes from the study of the CD4+ T-cell pop-
ulation that drives experimental autoimmune encephalomyelitis
(EAE) in the mouse central nervous system (CNS). Observations
that this cardinal “Th1-driven” disease was independent of either
IFN-γ or IL-12 [2, 3], led to the appreciation of the indispensible
role of IL-23 [4] and, ultimately, to the characterization of the
IL-17-producing, ROR-γt-expressing, Th17 subset and its impor-
tance in EAE [5]. This fits with data from cytokine-deficient mice
revealing that, as well as IL-23 and ROR-γt, both IL-6 and IL-1
(important factors in Th17 differentiation) are indispensible for
C© 2013 The Authors. European Journal of Immunology published byWILEY-VCHVerlag GmbH&Co. KGaA
Weinheim.
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EAE [5, 6]. Nevertheless, interrogation of the T-cell infiltrate in
the CNS commonly reveals strong production of IFN-γ and expres-
sion of the Th1-master regulator T-bet. Moreover, T-bet has been
reported to be essential for EAE [7], even in passive transfer mod-
els involving administration of myelin-reactive Th17 cells [8]. This
paradox has been resolved by elegant fate-mapping studies that
revealed that the majority IFN-γ+ and T-bet+ T cells in the CNS
have previously expressed, but since extinguished, IL-17 [9,10].
The reported requirement for T-bet in EAE, whether driven by
Th1 or Th17 populations, promotes this transcription factor as a
potential alternative therapeutic target, beyond individual T-cell-
derived cytokines. In light of this, we sought to better understand
the role of T-bet in EAE, starting with the hypothesis that it would
have a key role in promoting or maintaining GM-CSF, which has
recently come to the fore as an essential product of pathogenic
T cells [11, 12]. We report that, while T-bet is required for the
IL-17→IFN-γ switch, this is not required for EAE development.
Results and discussion
T-bet is not required for the development of
autoimmune CNS inflammation
T-bet−/− mice developed EAE after immunization with the myelin
oligodendrocyte glycoprotein 35–55 peptide (pMOG). While there
was consistently a delay in disease onset in the absence of
T-bet (Fig. 1A), the peak severity of disease did not differ signif-
icantly between WT and T-bet−/− mice. IFN-γ was reduced (but
not totally absent) in T-bet−/− T cells in the CNS (Fig. 1B). In
contrast, IL-17 production was markedly elevated in the absence
of T-bet (Fig. 1B). As described in earlier fate-mapping studies
[9, 10], IFN-γ+ CNS T cells were almost entirely IL-17-negative
by the peak of disease in WT mice. In contrast, the fewer IFN-γ+
T cells in T-bet−/− mice were mainly also IL-17+. The frequencies
of GM-CSF+ CD4+ cells in the CNS did not differ between WT and
T-bet−/− mice (Fig. 1B, lower panels).
Recall responses to pMOG (Fig. 1C–H) showed reduced (but
not totally absent) IFN-γ, but elevated IL-17 from T-bet−/− spleno-
cytes. Dynamic changes in levels of IFN-γ production were evident
over time in WT mice, whereas IFN-γ production remained at a
low level in T-bet−/− mice. Thus, at 10 days after priming, IFN-γ
production was high in WT, but greatly impaired in T-bet−/−
splenocytes (Fig. 1C), but by 21 daysWT and T-bet−/− splenocytes
produced equivalent (low) levels of IFN-γ (Fig. 1F). Again, GM-
CSF productionwas not impaired in T-bet−/− mice (Fig. 1E andH).
We conclude that encephalitogenicity does not require T-bet
and that this might reflect maintained GM-CSF and/or enhanced
IL-17 production in its absence.
Pathogenicity of autoreactive Th1 cells is T-bet
dependent
Th1 cells, generated from naive T cells that have not passed
through the IL-17-producing stage that occurs in vivo after
Figure 1. T-bet is not required for the development of EAE. EAE was
induced in WT and T-bet−/− mice by immunization with pMOG in
CFA. (A) Clinical course of disease in WT (closed symbols) and T-bet−/−
(open symbols) mice. Clinical scores are pooled from five independent
experiments and represent a total of 36 WT and 65 T-bet−/− mice. (B)
pMOG-stimulated cytokine production by CNS-infiltrating CD4+ T cells
retrieved at day 14 postimmunization. (C–H) pMOG-stimulated produc-
tion of (C, F) IFN-γ (D and G) IL-17, and (E and F) GM-CSF by splenocytes
from WT (closed symbols) and T-bet−/− (open symbols) mice at day
10 and 21 postimmunization. Results shown are from one experiment
and are representative of three independent experiments with five to
six mice per group per experiment. Data are shown as mean ± SEM.
(C and D) p < 0.001 and (E and G) p < 0.05, two-way ANOVA with
Bonferroni posttest.
immunization, can induce EAE and also produce GM-CSF
[11, 12]. We therefore asked whether T-bet−/− T cells exposed
to Th1-promoting conditions (IL-12 and IL-18) would maintain
GM-CSF production and pathogenic function.
We first generated T cells for passive transfer from LNs of H-2b
mice that have been immunized with pMOG (Fig. 2A). WT IL-12-
conditioned cells transferred robust EAE, whereas T-bet−/− cells
did not transfer disease (Fig. 2B). At the time of their transfer,
WT IL-12-conditioned cells produced IFN-γ with very few staining
for IL-17. In their T-bet−/− counterparts, this pattern was reversed
(Fig. 2C). The transferred T-bet−/− cells seemed able to persist
in the spleen as indicated by a strong production of IL-17 upon
pMOG recall (while IFN-γ and GM-CSF production were reduced,
C© 2013 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.
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but not absent), compared to spleens of mice receiving WT cells
(Fig. 2D–F). The failure of IL-12-conditioned T-bet−/− cells to
drive EAE correlated with an inability to migrate to (or expand in)
the CNS as evidenced by poor representation of CD4+ or MHC-II+
CD11b+ cells in the CNS (Fig. 2G and H).
Using a second system, in which Th1 cells are generated from
na¨ıve myelin basic protein (MBP) responsive Tg4 TCR transgenic
T cells by MBP peptide stimulation in the presence of IL-12 and
IL-18 (Fig. 2I), we also found that passive EAE was dependent
on expression of T-bet in the transferred T cells (Fig. 2J). At the
time of transfer, the frequency of IFN-γ+ cells was reduced (but
not absent) in Tg4.Tbet−/− Th1 cells (Fig. 2K). The lack of a
profound increase in IL-17 expression by these cells (Fig. 2K) dif-
fered from the elevated IL-17 that was seen in pMOG-immunized
T-bet−/− cells (Fig. 1B, D, and G), even after in vitro exposure
to IL-12 (Fig. 2C). This difference is likely to reflect exposure to
IL-17-promoting factors (IL-1, IL-6, and IL-23) during in vivo prim-
ing of T-bet−/− mice, but not during the in vitro polarization of
Th1 cells from naive Tg4.T-bet−/− cells. GM-CSF production was
not impaired in Tg4.Tbet−/− Th1 cells (Fig. 2L). Again, lack of
disease reflected an inability of the transferred Tg4.Tbet−/− Th1
cells to accumulate in the CNS and their retention in the spleen
(Fig. 2M–O).
Pathogenicity of autoreactive Th17 cells is T-bet
independent
The phenotype of the T-bet−/− CNS T cells in active EAE (Fig. 1B)
suggested a population of stable Th17 cells. We therefore gener-
ated Th17-polarized cells and tested their requirement for T-bet to
induce EAE (Fig. 3). IL-23-conditioned T cells from pMOG-primed
LNs of T-bet−/− mice had high-IL-17 production and both WT and
T-bet−/− cultures showed strong expression of GM-CSF at the time
of transfer (data not shown) and were equally encephalitogenic,
providing indistinguishable clinical courses (Fig. 3B). We also gen-
erated Th17 cells from na¨ıve Tg4 T cells (Fig. 3C) and again found
that WT and T-bet−/− Tg4 cells were equally encephalitogenic
(Fig. 3D). Consistent with the paradigm in which IL-17+ T cells
begin to express T-bet, extinguish IL-17, and switch-on IFN-γ pro-
duction over the course of EAE, Tg4.WT Th17 cells had limited
IFN-γ production at the time of transfer, but had gained this func-
tion andwere IL-17-negative when retrieved from the CNS (Fig. 3E
and F). This shift in function did not occur in Tg4.T-bet−/− Th17
 Figure 2. Pathogenicity of Th1 cells is T-bet dependent. (A–H) EAE was
induced in C57BL/6 mice by passive transfer of WT or T-bet−/− IL-12-
conditioned pMOG-responsive cells. (B) Clinical course of disease is
shown. (C) IFN-γ and IL-17-producing capacity of cells on the day of
transfer was assessed by flow cytometry. (D–H) Cohorts of mice were
sacrificed at 12 days posttransfer to assess cytokine production andCNS
inflammation. The production of (D) IFN-γ, (E) IL-17, and (F) GM-CSF by
pMOG-stimulated splenocytes is shown. (E) p < 0.001 and (F) p < 0.05,
two-way ANOVA with Bonferroni posttest. (G) The numbers of CD4+
T cells in the CNS and (H) the percentage of CNS CD11b+ cells express-
ing MHC class II in recipients of WT (closed symbols) and T-bet−/− cells
(open symbols) are shown. (A–H) All data shown are from one exper-
iment representative of two independent experiments with six mice
per group per experiment. (I–O) EAE was induced in B10.PLxC57BL/6
mice by passive transfer of Th1-polarized Tg4.WT or Tg4.T-bet−/−
T cells. (J) Clinical course of disease is shown. Results shown are from
one experiment representative of three independent experiments with
eight to nine mice per group per experiment. Data are shown as mean
± SEM. (K) IFN-γ and IL-17 and (L) GM-CSF producing capacity of cells
on the day of transfer are shown. (M–O) The numbers of transferred Tg4
cells retrieved from (M) the CNS and (N) spleen at 14 days posttransfer
or (O) the CNS at 7 days posttransfer are shown.
C© 2013 The Authors. European Journal of Immunology published by
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Figure 3. Pathogenicity of Th17 cells is T-bet independent. (A and
B) EAE was induced in C57BL/6 mice by passive transfer of WT or
T-bet−/− IL-23-conditioned cells derived from the draining LNs of
pMOG-immunizedmice. (B) Clinical course of disease is shown. Results
are from one experiment representative of two independent experi-
ments with n = 5 per group per experiment. Data are shown as mean
±SEM. (C–G) EAE was induced in B10.PLxC57BL/6 mice by passive trans-
fer of Th17-polarized Tg4.WT or Tg4.T-bet−/− T cells. (D) Clinical course
of disease is shown. Results are from one experiment representative
of two independent experiments with 5–11 mice per group per experi-
ment. Data are shown as mean ± SEM. (E–G) Flow cytometric analysis
of cytokine production and transcription factor expression in Tg4.WT
and Tg4.T-bet−/− Th17 cells at the time of transfer and after retrieval
from the inflamed CNS at 19 days posttransfer. (E) IL-17 versus IFN-γ
production, (F) individual cytokines, and (G) T-bet and ROR-γt (G: gray
histograms show isotype control staining).
cells. Their IL-17 production was maintained in the CNS, with no
evidence for IFN-γ production (Fig. 3E and F).
Not only was T-bet required for the gain of IFN-γ production,
it was also necessary for the loss of IL-17 production by cells
retrieved from the CNS (Fig. 3E and F). This is consistent with the
CNS CD4+ cytokine profiles displayed byWT versus T-bet−/− mice
during pMOG-induced active EAE (Fig. 1B). There are two pos-
sible T-cell-intrinsic mechanisms for the loss of IL-17 production
when T-bet is present: (i) via the interaction of T-bet with runx1
preventing runx1-mediated transactivation of the Rorc promoter
[13]; (ii) by boosting IFN-γ production which in turn inhibits
IL-17 production [14]. Fitting with either scenario, whereas ROR-
γt expression was lost in WT Th17 cells retrieved from the CNS,
at least some of their T-bet−/− counterparts maintained ROR-γt to
pretransfer levels (Fig. 3G).
We have found no evidence for an impairment of proliferative
capacity in T-bet−/− T cells (data not shown), so we believe that
the absence of transferred T-bet−/− Th1 cells from the CNS most
likely reflects a failure inmigration. Expression of CCR6, which has
been proposed to facilitate Th17 cell entry into the CNS (reviewed
in [15]), was not affected by the lack of T-bet in Tg4 Th17 cells
(data not shown). As would be expected, T-bet deficiency did
impair expression of Th1-associated CXCR3 in Th1-polarized Tg4
cells (data not shown). However, we cannot currently conclude
that this accounts for the inability of T-bet−/− IL-12-conditioned
or Th1 cells to enter the CNS, because there is no consensus on the
importance of CXCR3 expression for Th1-induced EAE [15]. The
molecular basis for the failure of T-bet−/− Th1 cells to accumulate
in the CNS therefore remains to be provided.
Our data differ significantly from those recently reported by
Duhen et al. [16]. That report reasserted that mice with global
T-bet deficiency are resistant to EAE and implied possible neces-
sary roles for T-bet expression by non-T cells. We show that this is
not the case. Duhen et al. [16] used mice in which T-bet-deficiency
was controlled by the CD4 promoter and showed the same delayed
course of EAE that we see here with T-bet−/− mice. That report
also concluded that the ability to produce IFN-γ co-associated with
pathogenic function of Th17 cells, even in the absence of T-bet.
Here, we show that, in the absence of T-bet, Th17 cells can drive
EAE without the development of IFN-γ production. Subtle dif-
ferences in approach between the two studies might account for
these discrepancies. For example, Duhen et al. [16] used chronic
in vitro stimulation with IL-23 to engender IFN-γ production by
T-bet−/− Th17 cells. In contrast, our Th17 cells were wholly capa-
ble of pathogenic function without such extended in vitro manip-
ulation. However, the study by Duhen et al. does concur with ours
in the conclusion that T-bet is not critically involved in GM-CSF
production by pathogenic T cells.
Concluding remarks
There is an absolute requirement for the putative pathogenic
T cell in EAE to be sensitive to IL-6, IL-23, and IL-1 and to pro-
duce GM-CSF. Our data, combined with those of others [11, 12],
C© 2013 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.
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indicate that there is no gross deficiency in these critical features
in the absence of T-bet. Based on this, Th17-driven inflammation
should be unimpaired in T-bet−/− mice. This is what we find here.
While increased T-bet expression is certainly a characteristic of
pathogenic Th17 cells [17], we have shown definitively that it is
entirely nonessential for EAE development and that Th17 cells can
induce inflammatory pathology without co-opting those elements
of the Th1 transcriptional program under the control of T-bet.
Thus, T-bet may be a less attractive therapeutic target than it has
previously appeared.
Materials and methods
Mice, antigens, and tissue culture medium
C57BL/6, Tg4.CD45.1 (Tg4.WT) [18], T-bet−/− (obtained from
The Jackson Laboratory), and B10.PLxC56BL/6 mice were bred
under specific pathogen-free conditions at the University of
Edinburgh. T-bet−/− mice were crossed with Tg4.CD45.1 mice
to generate Tg4.T-bet−/− mice. All experiments were approved by
the University of Edinburgh ethical review committee and were
performed in adherence to UK legislation. Mice were screened
in-house, using the Jackson Labs protocol to confirm knock-
out status and independently by Transnetyx Inc. (Cordova, TN,
USA). pMOG (MEVGWYRSPFSRVVHLYRNNGK) and the MBP
Ac1–9 (Ac-ASQKRPSQR) peptide were synthesized by Cambridge
Research Biochemicals (Cleveland, UK). Tissue culture medium
was RPMI 1640 medium, supplemented with 2 mM L-glutamine,
100 U/mL penicillin, 100 μg/mL streptomycin, and 5 × 10−5 M 2-
ME (all from Invitrogen Life Technologies, Paisley, UK), and 10%
FCS (Sigma, Poole, UK).
Active induction of EAE
EAE was induced in H-2b (C57BL/6 and T-bet−/−) mice using
100 μg of pMOG35–55 peptide emulsified in CFA, as described
previously [19]. Clinical signs of EAE were assessed daily with the
following scoring system: 0, no signs; 1, flaccid tail; 2, impaired
righting reflex and/or gait; 3, partial hind limb paralysis; 4, total
hind limb paralysis; 5, hind limb paralysis with partial front limb
paralysis; 6, moribund or dead. Assessment of CNS (brain and
spinal cord) immune cells was as described previously [20].
Adoptive transfer of EAE
pMOG-reactive cells were generated from draining LN cells
10 days after immunization with pMOG35–55 and cultured at 4 ×
106 cells/mL in the presence of 10 μg/mL pMOG. pMOG-reactive
IL-12 conditioned cells [20], or IL-23 conditioning cells [21],
were prepared as previously described.
Tg4 splenocytes were cultured at 4 × 106 cells/mL with
10 μg/mL MBP (Ac1–9). Conditions for Th1 polarization [20] and
Th17 polarization [22] were as previously described. In all trans-
fer experiments, 4 × 106 blasts were injected into WT recipients.
Clinical signs of EAE were assessed as described above.
Antibodies and flow cytometry analysis
Cells were stained for flow cytometry using the indicated Abs.
Intracellular staining for cytokines and transcription factors was
performed as previously described [20]. Flow cytometry data were
collected on a Fortessa flow cytometer (BD Biosciences) and all
data were analyzed using FlowJo software (Tree Star, CA, USA).
In vitro restimulation and cell culture
A total of 8 × 105 splenocytes per well (in flat-bottom 96-well
microtiter plates) were cultured in X-VIVO-15TM tissue culture
medium (BioWhittaker, Wokingham, UK) and stimulated with
a dose range of pMOG. After 72-h culture, supernatants were
removed for determination of cytokine levels by ELISA.
Statistical analysis
Flow cytometry data were compared by unpaired t-test. ELISA
data were compared using two-way ANOVA with Bonferroni
posttesting.
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